Stock listing
NASDAQ:TCRX TScan Therapeutics, Inc. Stock
Home listing (NASDAQ) of TScan Therapeutics, Inc.
Follow TScan Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TCRX
$0.146 USD -0.003 (-1.7%)
Close on Nov 20, 2026
- Day range
- $0.140 – $0.155 USDNov 20, 2026
- Volume
- 391,711 sharesNov 20, 2026
- Market cap
- $9.27M USDAt the close on Nov 20, 2026 · price × 63.50M shares outstanding
- 52-week range
- $0.140 – $1.470 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $240,184 USDMedian day 559,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TCRX · Home | $0.146 USD | -0.003 (-1.7%) | 391,711 | $0.140 | $0.155 | $0.140 | $0.148 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TCRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.146 | -0.003 | -1.7% | $0.140 | $0.155 | $0.140 | 391,711 | |
| $0.148 | -0.003 | -1.7% | $0.152 | $0.165 | $0.142 | 409,284 | |
| $0.151 | +0.006 | +4.1% | $0.145 | $0.159 | $0.140 | 309,363 | |
| $0.145 | -0.015 | -9.7% | $0.161 | $0.168 | $0.145 | 404,580 | |
| $0.161 | -0.007 | -4.4% | $0.173 | $0.175 | $0.160 | 227,684 | |
| $0.168 | -0.018 | -9.5% | $0.183 | $0.183 | $0.160 | 714,485 | |
| $0.186 | +0.000 | +0.2% | $0.185 | $0.190 | $0.178 | 292,699 | |
| $0.185 | +0.004 | +2.0% | $0.185 | $0.199 | $0.175 | 581,570 | |
| $0.182 | -0.006 | -3.4% | $0.190 | $0.197 | $0.181 | 669,235 | |
| $0.188 | +0.006 | +3.4% | $0.186 | $0.189 | $0.177 | 277,314 | |
| $0.182 | -0.028 | -13.4% | $0.201 | $0.205 | $0.171 | 663,603 | |
| $0.210 | +0.021 | +11.1% | $0.198 | $0.212 | $0.189 | 640,139 | |
| $0.189 | +0.010 | +5.5% | $0.177 | $0.195 | $0.177 | 374,491 | |
| $0.179 | +0.005 | +2.7% | $0.181 | $0.190 | $0.175 | 497,329 | |
| $0.175 | -0.020 | -10.5% | $0.193 | $0.193 | $0.173 | 333,158 | |
| $0.195 | -0.004 | -2.0% | $0.194 | $0.197 | $0.185 | 57,870 | |
| $0.199 | +0.007 | +3.6% | $0.187 | $0.200 | $0.183 | 358,909 | |
| $0.192 | +0.002 | +1.2% | $0.190 | $0.197 | $0.183 | 539,679 | |
| $0.190 | -0.013 | -6.6% | $0.204 | $0.204 | $0.180 | 801,084 | |
| $0.203 | -0.013 | -6.0% | $0.221 | $0.227 | $0.202 | 262,800 | |
| $0.216 | -0.008 | -3.6% | $0.215 | $0.224 | $0.215 | 299,100 | |
| $0.224 | 0.000 | 0.0% | $0.220 | $0.224 | $0.212 | 688,200 | |
| $0.224 | +0.014 | +6.7% | $0.214 | $0.234 | $0.211 | 559,600 | |
| $0.210 | -0.021 | -9.1% | $0.238 | $0.238 | $0.210 | 368,300 | |
| $0.231 | -0.008 | -3.3% | $0.238 | $0.245 | $0.230 | 568,200 | |
| $0.239 | +0.028 | +13.3% | $0.216 | $0.243 | $0.209 | 878,800 | |
| $0.211 | -0.006 | -2.8% | $0.224 | $0.228 | $0.201 | 546,600 | |
| $0.217 | -0.021 | -8.8% | $0.240 | $0.240 | $0.212 | 461,400 | |
| $0.238 | 0.000 | 0.0% | $0.240 | $0.249 | $0.230 | 483,500 | |
| $0.238 | +0.010 | +4.4% | $0.228 | $0.247 | $0.228 | 869,300 | |
| $0.228 | -0.049 | -17.7% | $0.271 | $0.273 | $0.224 | 1,534,600 | |
| $0.277 | +0.002 | +0.7% | $0.271 | $0.283 | $0.263 | 542,100 | |
| $0.275 | -0.020 | -6.8% | $0.293 | $0.296 | $0.264 | 601,900 | |
| $0.295 | -0.026 | -8.1% | $0.317 | $0.330 | $0.285 | 749,900 | |
| $0.321 | +0.003 | +0.9% | $0.330 | $0.330 | $0.316 | 144,400 | |
| $0.318 | +0.003 | +1.0% | $0.319 | $0.329 | $0.311 | 622,700 | |
| $0.315 | -0.003 | -0.9% | $0.322 | $0.345 | $0.315 | 554,400 | |
| $0.318 | -0.022 | -6.5% | $0.339 | $0.346 | $0.311 | 753,200 | |
| $0.340 | 0.000 | 0.0% | $0.340 | $0.348 | $0.325 | 359,200 | |
| $0.340 | -0.009 | -2.6% | $0.352 | $0.370 | $0.330 | 381,900 | |
| $0.349 | -0.015 | -4.1% | $0.369 | $0.369 | $0.340 | 606,700 | |
| $0.364 | +0.009 | +2.5% | $0.360 | $0.372 | $0.341 | 1,081,000 | |
| $0.355 | +0.024 | +7.3% | $0.333 | $0.360 | $0.330 | 918,500 | |
| $0.331 | +0.019 | +6.1% | $0.311 | $0.342 | $0.311 | 752,900 | |
| $0.312 | -0.022 | -6.6% | $0.343 | $0.357 | $0.310 | 1,143,200 | |
| $0.334 | +0.003 | +0.9% | $0.335 | $0.362 | $0.324 | 1,096,300 | |
| $0.331 | +0.010 | +3.1% | $0.330 | $0.340 | $0.321 | 883,900 | |
| $0.321 | +0.015 | +4.9% | $0.316 | $0.322 | $0.290 | 677,200 | |
| $0.306 | -0.014 | -4.4% | $0.320 | $0.334 | $0.306 | 1,104,000 | |
| $0.320 | +0.002 | +0.6% | $0.324 | $0.325 | $0.306 | 873,100 | |
| $0.318 | -0.012 | -3.6% | $0.320 | $0.350 | $0.310 | 804,600 | |
| $0.330 | -0.015 | -4.3% | $0.340 | $0.343 | $0.330 | 704,200 | |
| $0.345 | -0.047 | -12.0% | $0.380 | $0.380 | $0.330 | 1,536,300 | |
| $0.392 | +0.021 | +5.7% | $0.370 | $0.417 | $0.365 | 1,674,000 | |
| $0.371 | -0.010 | -2.6% | $0.381 | $0.402 | $0.351 | 3,091,000 | |
| $0.381 | -0.285 | -42.8% | $0.550 | $0.570 | $0.360 | 8,517,400 | |
| $0.666 | -0.064 | -8.8% | $0.723 | $0.770 | $0.656 | 820,300 | |
| $0.730 | -0.024 | -3.2% | $0.750 | $0.766 | $0.721 | 330,100 | |
| $0.754 | +0.004 | +0.5% | $0.755 | $0.780 | $0.750 | 150,700 | |
| $0.750 | -0.027 | -3.5% | $0.777 | $0.800 | $0.747 | 287,800 | |
| $0.777 | -0.017 | -2.1% | $0.778 | $0.792 | $0.774 | 68,300 | |
| $0.794 | -0.005 | -0.6% | $0.792 | $0.811 | $0.777 | 180,600 | |
| $0.799 | +0.019 | +2.4% | $0.790 | $0.800 | $0.768 | 194,400 | |
| $0.780 | +0.004 | +0.5% | $0.790 | $0.790 | $0.772 | 136,200 | |
| $0.776 | +0.026 | +3.5% | $0.750 | $0.789 | $0.750 | 338,300 |
- Ticker
- NASDAQ:TCRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Sep 2, 2026
Investor Presentation (September 2026)
Investor deck · 21 slides
Latest news
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 12, 2026
Closed $0.168 (-9.5%) on Nov 12, 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
Sep 2, 2026
Closed $0.381 (-42.8%) on Sep 2, 2026
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 12, 2026
Closed $0.773 (-0.5%) on Aug 12, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Jul 30, 2026
Closed $0.756 (+1.9%) on Jul 30, 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 24, 2026
Closed $0.881 (-4.3%) on Jun 24, 2026
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Jun 22, 2026
Closed $0.865 (-6.0%) on Jun 22, 2026
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Jun 3, 2026
Closed $0.972 (-0.8%) on Jun 3, 2026
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
Closed $1.25 (+3.3%) on May 6, 2026
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
Apr 27, 2026
Closed $1.26 (-3.8%) on Apr 28, 2026
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Apr 8, 2026
Closed $1.06 (-0.9%) on Apr 8, 2026
TScan Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 100 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 15 decks · latest Sep 2, 2026
Where TScan Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TCRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TCRX | BOATS | United States | USD |
Valuation
EV/sales −5.9× against a median of 8.6×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$30.80M USD
- P/E
- Loss
- EV/sales
- −5.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- −561.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.9×
- Beta vs S&P 500
- 1.66
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Alzinova AB · OMXSTO:ALZ | US$9.57M | US$8.34M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| CytoMed Therapeutics Limited · NASDAQ:GDTC | US$9.01M | US$8.23M | n/a | 14.7× | n/a | 2.3× | −730.3% | 0.1× | 0.16 |
| PreveCeutical Medical Inc · CSE:PREV | US$8.97M | US$8.95M | n/a | n/a | n/a | n/a | n/a | n/a | 0.73 |
| BioLineRX Ltd. · TASE:BLRX | US$8.90M | US$10.13M | n/a | 8.6× | n/a | 0.5× | −171.7% | 0.3× | n/a |
| Median of the others | US$9.37M | US$8.65M | 8.6× | 0.8× | −328.0% | 0.0× | 0.69 |
Forecasts
1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.79 · 4 analysts
- Revenue, year to Dec 2026
- 3.22M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gavin MacBeath | Chief Executive Officer |
| Zoran Zdraveski | Chief Legal and Strategy Officer and Secretary |
| Caileigh Dougherty | AVP, Head of Corporate Communications & Investor Relations |
| Caileigh DoughertyAVP | Head of Corporate Communications & Investor Relations |
| TScan Therapeutics | Investor Relations |
| Cagan Gurer | Senior Vice President, Discovery |
| Shrikanta Chattopadhyay | Senior Vice President, Head of Translational Medicine |
| Ann Hargraves | Chief Human Resources Officer |
| Jim Murray | Chief Development Operations Officer |
Board
| Director | Role |
|---|---|
| Gavin MacBeath | Chief Executive Officer |
| Zoran Zdraveski | Chief Legal and Strategy Officer and Secretary |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −9.5% |
| Q2 2026 | Aug 12, 2026 · Before open | −0.5% |
| Q1 2026 | May 6, 2026 · Before open | +3.3% |
| Q4 2025 | Mar 11, 2026 | −4.2% |
| Q3 2025 | Nov 12, 2025 · Before open | −2.5% |
| Q2 2025 | Aug 12, 2025 · Before open | +3.7% |
| Q1 2025 | May 6, 2025 · Before open | −9.3% |
| Q4 2024 | Mar 5, 2025 | +3.0% |
| Q3 2024 | Nov 12, 2024 · Before open | −4.9% |
| Q2 2024 | Aug 12, 2024 · Before open | +1.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +3.6% |
| Q4 2023 | Mar 6, 2024 · Before open | +1.7% |
| Q3 2023 | Nov 9, 2023 · Before open | −0.9% |
| Q2 2023 | Aug 10, 2023 · Before open | −2.3% |
| Q1 2023 | May 10, 2023 · Before open | +42.6% |
| Q4 2022 | Mar 8, 2023 · Before open | +0.6% |
| Q3 2022 | Nov 9, 2022 · Before open | −1.6% |
| Q2 2022 | Aug 10, 2022 · Before open | −9.9% |
| Q1 2022 | May 9, 2022 · Before open | −8.3% |
| Q4 2021 | Mar 9, 2022 · Before open | +5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 21 slides | Sep 2, 2026 |
| Investor Presentation (September 2026) | Investor deck | 22 slides | September 2026 |
| Technical Presentation (June 2026) | Technical | 65 slides | Jun 22, 2026 |
| Corporate Update (June 2026) | Corporate update | 48 slides | June 2026 |
| Investor Presentation (January 2026) | Investor deck | 36 slides | Jan 12, 2026 |
| Technical Presentation (December 2025) | Technical | 30 slides | Dec 8, 2025 |
| ACR Convergence 2025 | Conference | 14 slides | October 2025 |
| Investor Presentation (September 2025) | Investor deck | 40 slides | Sep 9, 2025 |
| Tandem Meetings 2025 | Conference | 14 slides | February 2025 |
| Investor Day (December 2024) | Investor day | 51 slides | Dec 10, 2024 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ASH 2024 (American Society of Hematology Annual Meeting) | Conference | 14 slides | December 2024 |
| Investor Presentation (April 2024) | Investor deck | 47 slides | Apr 16, 2024 |
| Technical Presentation (December 2023) | Technical | 29 slides | Dec 11, 2023 |
| Investor Presentation (June 2023) | Investor deck | 61 slides | June 2023 |
| Investor Presentation (May 2022) | Investor deck | 39 slides | May 2022 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of pre-funded warrants Announced: about US$30M · US$4 a share · Warrants at US$0.0001 Buyers: Lynx1 Capital Management LP (with an investment fund advised by Lynx1, buying approximately $30 million of pre-funded warrants) Use of proceeds: Extend cash runway to fund operations into the first quarter of 2027 | Dec 26, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Jul 15, 2021.
- Price
- US$15.00 a share
- Shares offered
- 6,666,667 shares of common stock
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,000,000 more shares
- Underwriters
- MORGAN STANLEY, JEFFERIES, COWEN, BARCLAYS · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 19, 2021 |
| Filed publicly | Apr 23, 2021 |
| Amended 4 times | Newest Jul 12, 2021 |
| Shares registered with an exchange | Jul 13, 2021 |
| Declared effective by the SEC | Jul 15, 2021 |
| Final prospectus, with the price | Jul 19, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 19, 2021 |
| FWP · Free writing prospectus | Jul 16, 2021 |
| EFFECT · Notice that a registration is effective | Jul 15, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 15, 2021 |
| CERT · Exchange's certificate of listing | Jul 15, 2021 |
| CORRESP · Letter to the SEC | Jul 14, 2021 |
| UPLOAD · Letter from the SEC | Jul 13, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
All 23 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jul 12, 2021 |
| S-1/A · Registration statement, amended | May 14, 2021 |
| CORRESP · Letter to the SEC | May 5, 2021 |
| S-1/A · Registration statement, amended | May 5, 2021 |
| UPLOAD · Letter from the SEC | May 3, 2021 |
| CORRESP · Letter to the SEC | Apr 30, 2021 |
| S-1/A · Registration statement, amended | Apr 30, 2021 |
| CORRESP · Letter to the SEC | Apr 30, 2021 |
| UPLOAD · Letter from the SEC | Apr 29, 2021 |
| CORRESP · Letter to the SEC | Apr 23, 2021 |
| S-1 · Registration statement | Apr 23, 2021 |
| UPLOAD · Letter from the SEC | Apr 15, 2021 |
| DRS · Draft registration statement | Mar 19, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 19, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.3M | 2.82M | 21.0M | 13.5M | 10.1M | 1.08M | 0 |
| Cost of revenue | 2.87M | 4.11M | 88.2M | 5.14M | 3.33M | 20.6M | 9.44M |
| Gross profit | 7.46M | 2.82M | 21.0M | 13.5M | 10.1M | -19.5M | -9.44M |
| Research and development | 114.2M | 107.3M | 88.2M | 59.8M | 45.0M | 20.6M | 9.44M |
| Selling, general and administrative | 32.0M | 29.6M | 25.5M | 20.4M | 13.8M | 6.74M | 4.77M |
| Operating income | -135.8M | -134.8M | -93.5M | -66.6M | -48.6M | -26.2M | -14.2M |
| Depreciation and amortization | 2.90M | 4.10M | 5.40M | 5.10M | 3.30M | 1.20M | 519.0K |
| EBITDA | -132.9M | -130.7M | -88.1M | -61.5M | -45.3M | -25.0M | -13.7M |
| Interest expense | 2.77M | 3.65M | 3.76M | 1.18M | 16.0K | 0 | 0 |
| Income before tax | -129.8M | -127.5M | -89.2M | -66.2M | -48.6M | -26.1M | -13.7M |
| Income tax | 0 | 5.19M | -415.0K | 3.09M | -106.0K | -552.0K | |
| Net income | -129.8M | -127.5M | -89.2M | -66.2M | -48.6M | -26.1M | -13.7M |
| Earnings per share, basic | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 | -28.52 | -0.55 |
| Earnings per share, diluted | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 | -28.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 152.4M | 178.7M | 133.4M | 120.0M | 161.4M | 34.8M | 41.8M |
| Short-term investments | 0 | 111.4M | 58.7M | 0 | |||
| Current assets | 157.2M | 292.7M | 194.2M | 124.1M | 165.7M | 36.4M | 42.4M |
| Property, plant and equipment | 8.71M | 7.24M | 7.74M | 10.1M | 11.8M | 5.66M | 6.41M |
| Total assets | 228.8M | 371.1M | 272.1M | 199.1M | 188.1M | 49.7M | 49.4M |
| Accounts payable | 1.24M | 4.28M | 2.37M | 2.91M | 1.76M | 2.91M | 1.01M |
| Current liabilities | 18.7M | 36.0M | 29.8M | 17.3M | 21.3M | 17.4M | 2.40M |
| Long-term debt | 32.5M | 32.1M | 26.7M | 29.3M | |||
| Total debt | 32.5M | 32.1M | 30.0M | 29.3M | 6.04M | 7.43M | 4.89M |
| Total liabilities | 105.7M | 130.1M | 121.3M | 99.7M | 27.3M | 32.5M | 6.84M |
| Shareholders' equity | 123.1M | 241.0M | 150.9M | 99.4M | 160.8M | -42.5M | 42.5M |
| Shares outstanding | 129.9M | 112.0M | 65.6M | 24.0M | 23.9M | 1.14M | 24.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -135.3M | -110.8M | -61.4M | -66.5M | -48.7M | -3.02M | -12.5M |
| Capital spending | -4.41M | -3.83M | -3.15M | -4.22M | -9.94M | -4.24M | -1.25M |
| Free cash flow | -139.7M | -114.6M | -64.5M | -70.7M | -58.6M | -7.26M | -13.8M |
| Cash from investing | 109.4M | -52.6M | -60.8M | -4.22M | -9.94M | -4.24M | -1.25M |
| Cash from financing | -336.0K | 208.8M | 135.4M | 29.4M | 189.7M | 288.0K | 34.8M |
| Dividends paid | 0 | 0 | |||||
| Share buybacks | 264.0K | 326.0K | 189.7M | ||||
| Change in cash | -26.3M | 45.3M | 13.3M | -41.4M | 131.1M | -6.97M | 21.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Oct 26, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 25, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 11, 2026 | Management or board change | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 8-K · Current report | May 22, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 7, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 26, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | May 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 14, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 11, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 5, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 26, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 26, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 8-K · Current report | Nov 21, 2024 | Financing | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 1, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Oct 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 23, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 30, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Apr 29, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 23, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Apr 17, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 17, 2024 | Results | SEC |
| FWP · Free writing prospectus | Apr 17, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 16, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 16, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2024 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 10, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 8, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Mar 7, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 6, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 8, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 7, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 24, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 24, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 29, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 16, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 12, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 8, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 6, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 5, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jun 5, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 2, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 2, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 2, 2023 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jun 2, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 8-K · Current report | May 31, 2023 | Material contract | SEC |
| 8-K · Current report | May 31, 2023 | Management or board change | SEC |
| 424B5 · Prospectus | May 26, 2023 | Offer document | SEC |
| FWP · Free writing prospectus | May 26, 2023 | Offer document | SEC |
| 424B5 · Prospectus | May 25, 2023 | Offer document | SEC |
| 8-K · Current report | May 17, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 17, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 17, 2023 | Other filings | SEC |
| 8-K · Current report | May 16, 2023 | Current report | SEC |
| 424B5 · Prospectus | May 16, 2023 | Offer document | SEC |
| AW | May 16, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 15, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 15, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 15, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 15, 2023 | Offer document | SEC |
| S-3/A · Registration statement, amended | May 15, 2023 | Offer document | SEC |
This page holds 200 of 336 filings. Open Filings
Cap table
Built by 6ix from TScan Therapeutics, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 63,502,657
- Fully diluted
- 125,749,364
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 63,502,657 | Sep 30, 2026 |
| Warrants | 62,246,707 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 63,502,657 |
| Sep 30, 2026 | 67,779,255 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Felix Baker Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past) | Director · Since at least Jul 15, 2021 |
| Julian Baker Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past) | Director · Since at least Jul 15, 2021 |
| Timothy J Barberich Other companies: Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Rocket Pharmaceuticals, Inc. (Director · Sep 28, 2016 – Jun 20, 2017 · Past); Eledon Pharmaceuticals, Inc. (Director · Sep 16, 2014 – Jun 15, 2016 · Past); Verastem, Inc. (Director · Mar 10, 2014 – Jun 28, 2021 · Past); HeartWare International Inc (Director · Apr 29, 2008 – Aug 23, 2016 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Director · Mar 16, 2006 – Oct 20, 2009 · Past) | Director · Jul 15, 2021 – Dec 18, 2023 · Past |
| Garry A Nicholson Other companies: Day One Biopharmaceuticals Inc (Director · Since at least Sep 12, 2022); NextCure, Inc. (Director · Jun 24, 2021 – Jun 22, 2023 · Past); G1 Therapeutics Inc (Director · Jun 17, 2021 – Sep 18, 2024 · Past); Turning Point Therapeutics Inc (Director · Jun 2, 2021 – Aug 17, 2022 · Past); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past) | Director · Since at least Jun 12, 2024 |
| Katina Dorton Other companies: Prelude Therapeutics Incorporated (Director · Since at least Oct 17, 2025); Mallinckrodt Inc (Director · Since at least Feb 2, 2024); Fulcrum Therapeutics, Inc. (Board Member · Since at least Jun 9, 2021); US Ecology Inc (Director · May 26, 2021 – May 2, 2022 · Past); Pandion Therapeutics Inc (Director · Dec 2, 2020 – Apr 1, 2021 · Past) | Director · Since at least Jul 15, 2021 |
| Keith Woods Other companies: Neurogene Inc. (Director · Since at least Jun 12, 2025); Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); X4 Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023); Rocket Pharmaceuticals, Inc. (Director · Dec 7, 2023 – Jun 13, 2024 · Past) | Director · Since at least Dec 6, 2023 |
| Jason Amello Other companies: Candel Therapeutics, Inc. (Chief Financial Officer · Sep 21, 2022 – Nov 28, 2023 · Past); Acer Therapeutics Inc (Director · Jan 2, 2020 – Mar 14, 2023 · Past); Akebia Therapeutics, Inc. (SVP, CFO & Treasurer · Apr 11, 2019 – Feb 28, 2020 · Past) | Chief Financial Officer · Since at least Jan 29, 2024 |
| Gabriela Gruia Other companies: Aprea Therapeutics, Inc. (Director · Since at least May 5, 2023); Molecular Templates Inc (Director · Mar 1, 2022 – Sep 27, 2024 · Past) | Director · Since at least Jul 15, 2021 |
| Ann Hargraves | Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Cagan Gurer | Senior Vice President, Discovery · Since at least Apr 27, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Caileigh Dougherty | AVP, Head of Corporate Communications & Investor Relations · Since at least Sep 2, 2026 |
| Caileigh DoughertyAVP | Head of Corporate Communications & Investor Relations · Since at least Jun 22, 2026 |
| Christoph H Westphal | Director · Jul 15, 2021 – Jul 15, 2021 · Past |
| Chrystal Louis | Chief Medical Officer · Since at least Apr 22, 2024 |
| Debora Barton | Chief Medical Officer · Jul 5, 2022 – Jun 13, 2023 · Past |
| Gavin MacBeath | Chief Executive Officer · Since at least Jan 20, 2026 |
| Heather SavelleTScan Therapeutics | Inc.VP · Dec 26, 2024 – Nov 4, 2026 · Past |
| Ittai Harel | Director · Jul 15, 2021 – Jun 1, 2022 · Past |
| Jim Murray | Chief Development Operations Officer · Since at least Nov 5, 2024 |
| Leiden Dworak | See Remarks · Since at least Jul 21, 2023 |
| Shrikanta Chattopadhyay | Senior Vice President, Head of Translational Medicine · Since at least Sep 17, 2025 |
| Stephen Camiolo | Senior Vice President, Market Access · Mar 27, 2025 – Nov 4, 2026 · Past |
| TScan Therapeutics | Investor Relations · Since at least Feb 25, 2026 |
| William Desmarais | Chief Business Officer · Jul 15, 2021 – Jul 25, 2022 · Past |
| Zoran Zdraveski | Chief Legal and Strategy Officer and Secretary · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about TScan Therapeutics, Inc.